PIPELINE

PHARMA

  • E. hallii: as basis of a drug to treat Type 2 diabetes has already been tested in 3 clinical trials in MetS/prediabetes and the next trial in Type 2 diabetes is scheduled to start in the first half of 2021
  • Intestinimonas: as basis of a drug to treat Type 2 Diabetes has been tested in animal trials; a first clinical Proof of Concept study will start in Q4/2020
  • CH-0301: the third drug intervention is based on FMT in Type 1 Diabetes; first aim is to confirm the clinical data, which were generated in the FMT discovery study
  • CH-0701: the fourth drug intervention is based on FMT in Cancer cachexia; the primary objective is to extend the application of FMT to late and earlier stage cancer patients

FOOD

  • E. hallii: as basis of a food supplement as intervention in subjects suffering from Metabolic syndrome/prediabetes; this product is in the most advanced stage, currently running a pivotal study in 100 subjects in both US and Europe.
  • Intestinimonas: as basis of a food supplement as intervention in subjects suffering from Metabolic syndrome/prediabetes; the first clinical Proof of Concept study in MetS will start in Q4/2020.
  • Anaerostipes rhamnosivorans: this newly identified microorganism is also indicated as intervention in Metabolic Syndrome